Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of Acquired Fusion Mutations in EGFR-TKIs-Resistant Patients with Advanced Lung Cancer.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP - 1 Mar 2026

Yang Yuan, Zhang Nana, Shi Liang, Chen Zhaoxin, Lu Baohua, Liu Zhe

Abstract excerpt

To determine the characteristics of non-small cell lung cancer (NSCLC) patients with fusion genes emerging after resistance to EGFR-TKIs. This study retrospectively collected 2800 cases of NSCLC with EGFR-sensitive mutations who underwent tissue-based next- generation sequencing (NGS) testing at least once. Patients with acquired fusion mutations, including ALK, ROS1, RET, etc., were included in the study, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-ret

Source

Identifiers

PMID: 41781838
DOI: 10.29271/jcpsp.2026.03.402

Genes

EGFR
ALK
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of Acquired Fusion Mutations in EGFR-TKIs-Resistant Patients with Advanced Lung Cancer.PMID 41781838Read ↗

Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIsSemantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implicationsSemantic proximity Read ↗

Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.Semantic proximity Read ↗

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.Semantic proximity Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.Semantic proximity Read ↗

Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice.Semantic proximity Read ↗

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.